Mounjaro expanded to include weight management - RACGP
The TGA approved tirzepatide (Mounjaro) for weight management in adults with BMI ≥30 kg/m2 or ≥27 kg/m2 plus comorbidities. Mounjaro, already used for type 2 diabetes, now supports weight loss and maintenance with a reduced-calorie diet and increased physical activity. Eli Lilly Australia aims to boost production by 150% in H2 2024 to meet demand, despite current shortages until August 2024. Mounjaro remains on private prescription, not PBS, starting at $395/month.
Reference News
The TGA approved tirzepatide (Mounjaro) for weight management in adults with BMI ≥30 kg/m2 or ≥27 kg/m2 plus comorbidities. Mounjaro, already used for type 2 diabetes, now supports weight loss and maintenance with a reduced-calorie diet and increased physical activity. Eli Lilly Australia aims to boost production by 150% in H2 2024 to meet demand, despite current shortages until August 2024. Mounjaro remains on private prescription, not PBS, starting at $395/month.